News & Press
GeNeuro: financial information and business update for the fourth quarter 2019
Geneva, Switzerland, January 30, 2020 – 6:00pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced its cash position at December 31, 2019, issued a business update and provided an outlook on its 2020 activities.
GeNeuro: upcoming investor meetings in San Francisco during the J.P. Morgan Healthcare Conference and in Paris at Biomed Event
Geneva, Switzerland, January 9, 2020 – 5:50pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases will participate to the LifeSci Advisors Corporate Access Event from January 13 to 16, 2020, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.
https://geneuro.ch/data/news/2020.01.09-GeNeuro-PR-investor-meetings-eng.pdf